GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Shiller PE Ratio

Zealand Pharma A/S (Zealand Pharma A/S) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma A/S Shiller PE Ratio Historical Data

The historical data trend for Zealand Pharma A/S's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Shiller PE Ratio Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zealand Pharma A/S's Shiller PE Ratio

For the Biotechnology subindustry, Zealand Pharma A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Shiller PE Ratio falls into.



Zealand Pharma A/S Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zealand Pharma A/S's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Zealand Pharma A/S's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.541/118.4000*118.4000
=-0.541

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.385 99.700 -0.457
201409 0.128 99.700 0.152
201412 -0.461 99.400 -0.549
201503 -0.355 100.200 -0.419
201506 -0.512 100.300 -0.604
201509 -0.333 100.200 -0.393
201512 0.445 99.800 0.528
201603 -0.488 100.200 -0.577
201606 -0.619 100.600 -0.729
201609 -0.194 100.200 -0.229
201612 0.309 100.300 0.365
201703 -0.148 101.200 -0.173
201706 -0.557 101.200 -0.652
201709 -0.242 101.800 -0.281
201712 -0.577 101.300 -0.674
201803 -0.525 101.700 -0.611
201806 -0.563 102.300 -0.652
201809 4.686 102.400 5.418
201812 -0.648 102.100 -0.751
201903 -0.625 102.900 -0.719
201906 -0.655 102.900 -0.754
201909 -0.507 102.900 -0.583
201912 -0.806 102.900 -0.927
202003 -0.736 103.300 -0.844
202006 -0.237 103.200 -0.272
202009 -0.912 103.500 -1.043
202012 -1.583 103.400 -1.813
202103 -0.925 104.300 -1.050
202106 -1.113 105.000 -1.255
202109 -0.729 105.800 -0.816
202112 -0.986 106.600 -1.095
202203 -0.764 109.900 -0.823
202206 -1.568 113.600 -1.634
202209 -0.427 116.400 -0.434
202212 -0.960 115.900 -0.981
202303 -0.541 117.300 -0.546
202306 -0.800 116.400 -0.814
202309 0.176 117.400 0.177
202312 -0.673 116.700 -0.683
202403 -0.541 118.400 -0.541

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma A/S  (OTCPK:ZLDPF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zealand Pharma A/S Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.